How HealthTech Companies Are Valued
I've sat across the table from healthtech founders pitching valuations of an ARR multiple and from buyers offering an ARR multiple for the exact same business. The spread isn't random, it's about reimbursement durability, clinical evidence, and whether the buyer believes the growth curve is real or pulled forward by COVID. Telehealth, RPM, digital therapeutics, and patient engagement each carry their own pricing logic.
The Post-Teladoc Reality
The Teladoc/Livongo writedown reset the entire public healthtech multiple framework. TDOC now trades at a revenue-multiple range (down from 25x+ at peak). Hims & Hers (HIMS) sits at 2-3x, Doximity (DOCS) at 8-12x because of its 50%+ EBITDA margins, and Phreesia (PHR) at 3-5x. Private deals run at premiums to publics, but the days of an ARR multiple for an unprofitable telehealth startup with 80% growth are over.
Today, sub-$25M ARR healthtech companies trade at a revenue-multiple range, with the multiple driven by growth rate, gross margin, and net retention. A company growing 60%+ with 75%+ gross margins and 110%+ NRR can still command the high end. A company growing 25% with 50% gross margins lands at the bottom.
The Three Healthtech Tiers
Telehealth and virtual care is the most price-disciplined segment. The COVID growth has fully normalized, and reimbursement parity legislation in many states has expired. Buyers value telehealth on a revenue-multiple range at SMB scale, 5-9x mid-market. Specialty telehealth (mental health, dermatology, GLP-1) commands premiums of 8-12x because the unit economics are better.
Remote patient monitoring (RPM) and digital therapeutics benefit from CMS reimbursement codes (CPT 99453/54/57/58 for RPM) that have created sustainable economics. RPM platforms with 20K+ enrolled patients, payer contracts, and EHR integration trade at a revenue-multiple range. Digital therapeutics with FDA clearance and published clinical evidence (Pear Therapeutics' structure, before bankruptcy) can command 10-15x, but Pear's collapse showed that clearance without reimbursement is worth nothing.
Workflow software and patient engagement is the most stable category. Companies selling to providers (scheduling, intake, billing automation, prior auth) trade at SaaS-equivalent multiples: 4-8x SMB, 8-15x mid-market for category leaders. This is where the institutional money is going right now because the unit economics look like real software, not healthcare.
Key Value Drivers I Look For
Reimbursement durability is the first question every buyer asks. Are the CPT codes durable? Has the payer been billed against them for 3+ years? Is there state-by-state reimbursement parity? Companies dependent on temporary COVID-era billing flexibilities are being valued at 50-70% discounts to those with durable reimbursement.
Health system contract penetration drives mid-market multiples. A platform with 30+ named health system customers and 90%+ logo retention is fundamentally different from one with 200 small clinic customers. The enterprise customers signal product-market fit and create acquisition value for strategics like Optum, Oracle Health (Cerner), and Epic ecosystem buyers.
Clinical evidence and outcomes data matter for any company touching clinical decision-making. Published peer-reviewed studies, real-world evidence registries, and outcomes data are how you defend a 10x+ multiple. Buyers like Welsh Carson, Frazier Healthcare, and General Atlantic explicitly diligence the clinical evidence package.
EHR integration depth is the moat for B2B platforms. Native Epic Connection Hub, Cerner Open Developer Experience, and athenahealth Marketplace integrations command premiums because the switching cost is real. Bolt-on integrations via FHIR APIs without workflow embedding don't carry the same value.
What Decreases HealthTech Value
Reimbursement uncertainty is the biggest discount driver. If your revenue depends on a billing code that may not exist in 24 months, expect a 40-60% multiple haircut and an aggressive earnout. CMS rate cuts to specific RPM/RTM codes have already crushed several deals I've been close to.
Long sales cycles and CAC payback over 24 months signal an enterprise sales model that isn't scaling efficiently. Buyers want to see CAC payback under 18 months for a 6x+ multiple, under 12 months for double-digit multiples.
EHR vendor competition is a permanent risk. Epic and Oracle Health can launch competing modules and bundle them into existing customer contracts. Companies in scheduling, patient intake, and basic patient engagement are most exposed. Buyers price this in.